Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.
Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs
Satomi Konno, Takuya Kishi
In these two years, coronavirus disease 2019 (COVID-19) has come to be a global pandemic. Patients with COVID-19 often require clinical isolation for preventing the spread of infection, and clinical isolation often prevents the patients and the family to be with their loved ones when they die. Moreover, patients with heart failure are affected by COVID-19, resulting in increased mortality with a heavy burden on medical staff and healthcare resources. In this decade, palliative care has already been standard therapy for heart failure. Considering these backgrounds, palliative care should be provided to patients with heart failure and COVID-19 in the pandemic of COVID-19. Although there is no evidence showing the clinical and social benefits of palliative care for patients with heart failure and COVID-19, we summarized what is needed to provide optimal palliative and end-of-life care for patients with heart failure and COVID-19 complications in this COVID-19 pandemic and post-COVID-19 era.